RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Innate Pharma Stock

Innate Pharma EBIT 2024

Innate Pharma EBIT

-31.92 M EUR

Ticker

IPH.PA

ISIN

FR0010331421

WKN

A0LCUJ

In 2024, Innate Pharma's EBIT was -31.92 M EUR, a 151.97% increase from the -12.67 M EUR EBIT recorded in the previous year.

The Innate Pharma EBIT history

YEAREBIT (undefined EUR)
2028e38.05
2027e-25
2026e13.63
2025e0.84
2024e-31.92
2023-12.67
2022-16.43
2021-47.83
20201.08
2019-27.05
20185.15
2017-39.98
20167.57
2015-10.77
2014-19.97
2013-2.79
2012-3.39
2011-7.57
2010-13.69
2009-15.54
2008-11.01
2007-9.09
2006-7.24
2005-6.42
2004-5.02

Innate Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Innate Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innate Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innate Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Innate Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Innate Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Innate Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innate Pharma’s growth potential.

Innate Pharma Revenue, EBIT and net profit per share

DateInnate Pharma RevenueInnate Pharma EBITInnate Pharma Net Income
2028e175.84 M undefined38.05 M undefined0 undefined
2027e131.11 M undefined-25 M undefined0 undefined
2026e107.7 M undefined13.63 M undefined24.8 M undefined
2025e73.4 M undefined835,775 undefined2.18 M undefined
2024e35.66 M undefined-31.92 M undefined-29.43 M undefined
202351.9 M undefined-12.67 M undefined-7.57 M undefined
202249.58 M undefined-16.43 M undefined-58.1 M undefined
202112.11 M undefined-47.83 M undefined-52.81 M undefined
202056.16 M undefined1.08 M undefined-63.98 M undefined
201968.97 M undefined-27.05 M undefined-20.76 M undefined
201879.89 M undefined5.15 M undefined3.05 M undefined
201732.63 M undefined-39.98 M undefined-48.39 M undefined
201656.16 M undefined7.57 M undefined12.64 M undefined
201517.91 M undefined-10.77 M undefined-6.71 M undefined
2014907,000 undefined-19.97 M undefined-19.65 M undefined
201312.47 M undefined-2.79 M undefined-2.89 M undefined
201210.38 M undefined-3.39 M undefined-3.2 M undefined
20117.45 M undefined-7.57 M undefined-6.98 M undefined
2010210,000 undefined-13.69 M undefined-13.66 M undefined
20093.31 M undefined-15.54 M undefined-14.63 M undefined
20087.45 M undefined-11.01 M undefined-9.85 M undefined
20078.69 M undefined-9.09 M undefined-8.92 M undefined
20066.2 M undefined-7.24 M undefined-6.04 M undefined
20051.3 M undefined-6.42 M undefined-6.13 M undefined
20042.11 M undefined-5.02 M undefined-4.73 M undefined

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Innate Pharma's sales revenue. A higher gross margin percentage indicates that the Innate Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Innate Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Innate Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innate Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innate Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innate Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Innate Pharma Margin History

Innate Pharma Gross marginInnate Pharma Profit marginInnate Pharma EBIT marginInnate Pharma Profit margin
2028e94.5 %21.64 %0 %
2027e94.5 %-19.07 %0 %
2026e94.5 %12.65 %23.03 %
2025e94.5 %1.14 %2.97 %
2024e94.5 %-89.52 %-82.54 %
202394.5 %-24.41 %-14.59 %
202292.78 %-33.13 %-117.19 %
202174.69 %-394.86 %-436.01 %
202093.61 %1.92 %-113.94 %
201995.35 %-39.22 %-30.1 %
201895.22 %6.44 %3.82 %
201786.86 %-122.53 %-148.28 %
201694.92 %13.48 %22.51 %
201585.44 %-60.16 %-37.45 %
2014289.42 %-2,201.32 %-2,166.15 %
201321.09 %-22.37 %-23.18 %
20128.57 %-32.66 %-30.83 %
2011-53.29 %-101.61 %-93.69 %
2010-4,890.48 %-6,519.05 %-6,504.76 %
2009-305.14 %-469.49 %-441.99 %
2008-106.58 %-147.79 %-132.21 %
2007-81.47 %-104.6 %-102.65 %
2006-62.1 %-116.77 %-97.42 %
2005-326.15 %-493.85 %-471.54 %
2004-162.09 %-237.91 %-224.17 %

Innate Pharma Aktienanalyse

What does Innate Pharma do?

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Innate Pharma's EBIT

Innate Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Innate Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Innate Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Innate Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Innate Pharma stock

How much did Innate Pharma achieve in EBIT for the current year?

In the current year, Innate Pharma has achieved an EBIT of -31.92 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Innate Pharma.

How has the EBIT of Innate Pharma developed in recent years?

The EBIT of Innate Pharma has increased by 151.972% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Innate Pharma?

The EBIT of Innate Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Innate Pharma pay?

Over the past 12 months, Innate Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innate Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Innate Pharma?

The current dividend yield of Innate Pharma is .

When does Innate Pharma pay dividends?

Innate Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innate Pharma?

Innate Pharma paid dividends every year for the past 0 years.

What is the dividend of Innate Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innate Pharma located?

Innate Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innate Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innate Pharma from 9/22/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Innate Pharma pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Innate Pharma in the year 2023?

In the year 2023, Innate Pharma distributed 0 EUR as dividends.

In which currency does Innate Pharma pay out the dividend?

The dividends of Innate Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Innate Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Innate Pharma

Our stock analysis for Innate Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innate Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.